Comparative Pharmacology
Head-to-head clinical analysis: PRESTALIA versus RAMIPRIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRESTALIA versus RAMIPRIL.
PRESTALIA vs RAMIPRIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PRESTALIA is a fixed-dose combination of perindopril, an angiotensin-converting enzyme inhibitor, and amlodipine, a dihydropyridine calcium channel blocker. Perindopril inhibits ACE, reducing angiotensin II formation, leading to vasodilation and decreased aldosterone secretion. Amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, causing vasodilation and reduced peripheral resistance.
Ramipril is a prodrug that is hydrolyzed in the liver to its active metabolite ramiprilat, which inhibits angiotensin-converting enzyme (ACE), thereby decreasing angiotensin II production, reducing vasoconstriction, aldosterone secretion, and sodium retention.
One tablet orally once daily, preferably in the morning. PRESTALIA is a fixed-dose combination of perindopril arginine (2.5 mg, 5 mg, or 10 mg) and amlodipine (5 mg or 10 mg). Initial dose: 3.5 mg perindopril arginine/2.5 mg amlodipine or 5 mg perindopril arginine/5 mg amlodipine. Titrate based on blood pressure response. Maximum dose: 10 mg perindopril arginine/10 mg amlodipine.
Initial: 2.5 mg orally once daily; Maintenance: 2.5-20 mg/day in 1-2 divided doses; Maximum: 20 mg/day.
None Documented
Clinical Note
moderateRamipril + Torasemide
"The risk or severity of adverse effects can be increased when Ramipril is combined with Torasemide."
Clinical Note
moderateRamipril + Etacrynic acid
"The risk or severity of adverse effects can be increased when Ramipril is combined with Etacrynic acid."
Clinical Note
moderateRamipril + Furosemide
"The risk or severity of adverse effects can be increased when Ramipril is combined with Furosemide."
Clinical Note
moderateRamipril + Bumetanide
None Documented
Perindoprilat: 30–120 hours (terminal, prolonged in renal impairment; effective half-life for accumulation ~24h). Indapamide: 14–24 hours (terminal).
Terminal half-life of ramiprilat is 13–17 hours (prolonged to 50 hours in renal impairment). Accumulation half-life is 110 hours after multiple doses.
Perindopril: 75% renal (as perindoprilat), 25% biliary/fecal. Indapamide: 70% renal, 20% biliary/fecal.
Primarily renal (60% as unchanged drug and metabolites) and fecal (40% via biliary elimination).
Category C
Category D/X
ACE Inhibitor/Calcium Channel Blocker Combination
ACE Inhibitor
"The risk or severity of adverse effects can be increased when Ramipril is combined with Bumetanide."